Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Wigler

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
British Journal of Cancer|October 1, 1993
Classical disseminated Kaposi's sarcoma in HIV-negative patients; an unusually indolent subtypeI G Ron, A Kuten, N Wigler, et al.
Acta Obstetricia Et Gynecologica Scandinavica|April 16, 1998
The role of routine pelvic lymph node sampling in patients with stage I endometrial carcinoma: second thoughtsA Bar-Am, I G Ron, M Kuperminc, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trialJ Jassem, T Pieńkowski, A Płuzańska, et al.
Journal of Neuro-Oncology|June 9, 1999
Radiation therapy of metastatic spinal cord compression. Multidisciplinary team diagnosis and treatmentF Kovner, S Spigel, I Rider, et al.
American Journal of Clinical Oncology|July 28, 2001
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter studyI G Ron, N Wigler, R Borovik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancerM E R O'Brien, N Wigler, M Inbar, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
British Journal of Cancer|October 1, 1993
Classical disseminated Kaposi's sarcoma in HIV-negative patients; an unusually indolent subtypeI G Ron, A Kuten, N Wigler, et al.
Acta Obstetricia Et Gynecologica Scandinavica|April 16, 1998
The role of routine pelvic lymph node sampling in patients with stage I endometrial carcinoma: second thoughtsA Bar-Am, I G Ron, M Kuperminc, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trialJ Jassem, T Pieńkowski, A Płuzańska, et al.
Journal of Neuro-Oncology|June 9, 1999
Radiation therapy of metastatic spinal cord compression. Multidisciplinary team diagnosis and treatmentF Kovner, S Spigel, I Rider, et al.
American Journal of Clinical Oncology|July 28, 2001
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter studyI G Ron, N Wigler, R Borovik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancerM E R O'Brien, N Wigler, M Inbar, et al.
Pageof 2